ArticleFrontiers in aging neuroscience2026
Associations between inflammatory-lipid indices and clinical outcomes in ischemic stroke patients treated with mechanical thrombectomy.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Inflammation and dyslipidemia are critical in post-stroke prognosis. We conducted a comprehensive analysis of six common inflammatory-lipid indices to evaluate the associations between these indices and four clinical outcomes after mechanical thrombectomy (MT) for acute ischemic stroke (AIS), and to identify generalizable consistently associated markers for all four clinical outcomes. Methods: In this retrospective studyassociations between inflammatory-lipid indices, namely monocyte-to-high-density lipoprotein cholesterol ratio (MHR), platelet-to-HDL-C ratio (PHR), neutrophil-to-HDL-C (NHR), lymphocyte-to-HDL-C ratio (LHR), fibrinogen-to-HDL-C ratio (FHR), and C-reactive protein-to-HDL-C ratio (CRP/HDL-C), and four post-MT clinical outcomes comprised hemorrhagic transformation (HT), malignant cerebral edema (MCE) 90-day unfavorable outcome and all-cause mortality were evaluated using multivariable analyses. False discovery rate (FDR) correction was applied for multiple comparisons. NHR, which demonstrated consistent significance for all four clinical outcomes, was subjected to further analyses. Results: A total of 513 patients were included., demonstrated The incidences of HT, MCE, unfavorable outcome, and all-cause mortality were 30.6% (157), 22.6% (116), 54.8% (281), and 25.9% (133), respectively. The NHR was significantly associated with all four clinical outcomes (HT: odds ratio [OR] 1.079, 95% confidence interval [CI] 1.023-1.142, p-FDR = 0.034; MCE: OR 1.089, 95% CI 1.031-1.154, p-FDR = 0.008; unfavorable outcome: OR 1.177, 95% CI 1.098-1.269, p-FDR < 0.001; all-cause mortality: hazard ratio [HR] 1.047, 95% CI 1.012-1.084, p-FDR = 0.022). In the subgroup analysis for all-cause mortality, an interaction between NHR and TOAST classification was observed ( Conclusion: NHR may serve as a potentially useful complementary marker of post-MT HT, MCE, unfavorable outcome, and all-cause mortality. Its association with all-cause mortality appears stronger in patients with cardioembolic stroke. HT and MCE may act as mediators linking NHR to unfavorable outcomes. External validation is required to verify these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.